Brokers Set Expectations for Charles River Laboratories Intl. Inc’s Q1 2020 Earnings (NYSE:CRL)

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) – Stock analysts at SunTrust Banks issued their Q1 2020 EPS estimates for Charles River Laboratories Intl. in a research report issued on Thursday, February 13th. SunTrust Banks analyst S. Draper forecasts that the medical research company will post earnings per share of $1.55 for the quarter. SunTrust Banks also issued estimates for Charles River Laboratories Intl.’s Q2 2020 earnings at $1.84 EPS, Q3 2020 earnings at $1.93 EPS, Q4 2020 earnings at $2.22 EPS, FY2020 earnings at $7.54 EPS and FY2021 earnings at $8.79 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $2.01 EPS for the quarter, topping the Zacks’ consensus estimate of $1.83 by $0.18. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. The firm had revenue of $691.10 million during the quarter, compared to analysts’ expectations of $685.46 million. During the same period in the previous year, the business posted $1.49 earnings per share. The company’s revenue for the quarter was up 14.1% compared to the same quarter last year.

CRL has been the subject of a number of other reports. Bank of America cut shares of Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price objective for the company. in a research report on Friday, October 18th. Cfra lifted their price objective on shares of Charles River Laboratories Intl. from $165.00 to $180.00 and gave the stock a “strong-buy” rating in a research report on Tuesday. Barclays reaffirmed a “hold” rating and set a $170.00 price objective on shares of Charles River Laboratories Intl. in a research report on Wednesday. Robert W. Baird reaffirmed an “outperform” rating and set a $185.00 price objective (up from $165.00) on shares of Charles River Laboratories Intl. in a research report on Wednesday. Finally, Goldman Sachs Group raised shares of Charles River Laboratories Intl. from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $143.00 to $179.00 in a research report on Friday, January 10th. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $169.33.

CRL stock opened at $176.48 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 1.43 and a quick ratio of 1.20. The company has a fifty day moving average price of $157.46 and a two-hundred day moving average price of $141.17. Charles River Laboratories Intl. has a one year low of $123.17 and a one year high of $176.89. The stock has a market cap of $7.70 billion, a price-to-earnings ratio of 37.87, a price-to-earnings-growth ratio of 1.77 and a beta of 1.18.

Institutional investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its stake in Charles River Laboratories Intl. by 31.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 229,047 shares of the medical research company’s stock valued at $30,319,000 after purchasing an additional 54,841 shares in the last quarter. J.P. Marvel Investment Advisors LLC acquired a new position in Charles River Laboratories Intl. in the third quarter valued at about $4,186,000. BBVA USA Bancshares Inc. raised its stake in Charles River Laboratories Intl. by 16.4% in the third quarter. BBVA USA Bancshares Inc. now owns 6,627 shares of the medical research company’s stock valued at $878,000 after purchasing an additional 935 shares in the last quarter. Tygh Capital Management Inc. raised its stake in Charles River Laboratories Intl. by 117.7% in the third quarter. Tygh Capital Management Inc. now owns 67,261 shares of the medical research company’s stock valued at $8,903,000 after purchasing an additional 36,371 shares in the last quarter. Finally, BlackRock Inc. raised its stake in Charles River Laboratories Intl. by 1.6% in the second quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock valued at $661,344,000 after purchasing an additional 72,827 shares in the last quarter. 95.78% of the stock is owned by institutional investors.

In other news, VP Birgit Girshick sold 1,051 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $145.55, for a total value of $152,973.05. Following the completion of the sale, the vice president now owns 18,728 shares of the company’s stock, valued at $2,725,860.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP William D. Barbo sold 6,901 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $172.11, for a total transaction of $1,187,731.11. Following the completion of the sale, the vice president now directly owns 18,931 shares of the company’s stock, valued at approximately $3,258,214.41. The disclosure for this sale can be found here. In the last three months, insiders sold 19,622 shares of company stock valued at $3,328,849. 1.80% of the stock is currently owned by company insiders.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Compound Annual Growth Rate (CAGR)

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Baillie Gifford & Co. Raises Stock Position in Zuora Inc
Baillie Gifford & Co. Raises Stock Position in Zuora Inc
Baillie Gifford & Co. Has $18.43 Million Stock Holdings in Xylem Inc
Baillie Gifford & Co. Has $18.43 Million Stock Holdings in Xylem Inc
Baillie Gifford & Co. Sells 72,408 Shares of American Express
Baillie Gifford & Co. Sells 72,408 Shares of American Express
Baillie Gifford & Co. Purchases 507,932 Shares of Cemex SAB de CV
Baillie Gifford & Co. Purchases 507,932 Shares of Cemex SAB de CV
Baillie Gifford & Co. Trims Stock Holdings in Howard Hughes Corp
Baillie Gifford & Co. Trims Stock Holdings in Howard Hughes Corp
Redfin Corp  Stock Holdings Increased by Baillie Gifford & Co.
Redfin Corp Stock Holdings Increased by Baillie Gifford & Co.


 
© 2006-2020 Zolmax.